Introduction
We examined the relative effects of thyrotropin (TSH) and TSH receptor autoantibodies in the sera of patients with autoimmune thyroid disease on three TSH-lutropin/chorionic gonadotropin (LH/CG) receptor extracellular domain chimeras. Each chimera binds TSH with high affinity. Only the chimera with TSH receptor extracellular domains ABC (amino acids 1-260) had a functional (cAMP) response to thyroid stimulatory IgG. The (15) were cultured in 24-well culture plates (Costar Corp., Cambridge, MA) in Ham's F12 medium supplemented with 10% fetal calfserum, 100 U/ml penicillin, 40 ug/ml gentamicin, 2.5 ,g/ml fungizone, and 400 ug/ml G418 (Geneticin; Gibco Laboratories, Grand Island, NY) at 370C in an atmosphere of 95% air-5% CO2. At confluence, the cells were rinsed once with NaCl-free HBSS, pH 7.4 (5 mM KC1, 1.3 mM CaCI2, 0.4 mM MgSO4, 0.34 mM Na2HPO4, 0.44 mM KH2PO4, and 0.1% glucose), supplemented with 20 mM Hepes, and then incubated with IgG (I mg/ml) in NaCl-free HBSS supplemented with 20 mM Hepes, 0.4% BSA, and 1 mM 3-isobutyl-l-methylxanthine. Incubations were for 2 h at 37°C in air. Cyclic AMP released into the medium was measured by radioimmunoassay (19) . TSI activity (determined in duplicate or triplicate, as described in the text) was expressed as a percentage ofthe mean value of three normal IgG included as controls in each experiment. Values > 2 SD above the mean of the normal IgG were regarded as positive. In experiments to evaluate the effect of TSH binding-inhibitory antibodies on TSI activity, inhibitory IgG or pooled normal IgG (final concentration of 0.5 mg/ml) was added to IgG with thyroidstimulatory activity (final concentration of 0.5 mg/ml).
TSH binding inhibition assay. The assay was performed as previously described (6) with minor modifications. Bovine TSH (-30 U/mg protein) was radiolabeled with the Bolton-Hunter reagent (New England Nuclear, Boston, MA). CHO cells expressing the wild-type TSH receptor or TSH-LH/CG receptor chimeras were cultured in 24-well plates. Before use in the assay, the cells were rinsed three times with NaCl-free HBSS containing 250 mM sucrose and 0.25% BSA. Incubations were for 2 h at 37°C in air, in the same buffer supplemented with -10,000 cpm '251-TSH and I mg/ml IgG. TBI values were expressed as follows: [ 1 - (radioactivity of test IgG/radioactivity of normal IgG or assay buffer)] X 100(%). Values > 2 SD above the mean ofthree normal IgG included in each experiment were defined as positive.
IgG affinitypuri4fication with chimeric receptors. CHO cells expressing chimeric receptors (or, as a control, the plasmid pSV2NEO) in 100-mm diameter culture dishes were rinsed three times with NaCl-free HBSS with 250 mM sucrose and 0.25% BSA, and 4 ml of IgG (1 mg/ ml) in the same buffer was added. After incubation for 2 h at 370C, the medium was aspirated and the cells were quickly rinsed three times with ice-cold phosphate-buffered saline. Bound IgG was eluted by incubating the cells with 4 ml of 0.1 M glycine-HCl, pH 2.5 (30 min at room temperature with intermittent rocking). The solution containing IgG desorbed from the cells was neutralized with 1 ml 1 M Tris-HCI, pH 7.5, centrifuged for 20 min at 10,000 g to remove cell debris, and dialyzed against H20. The IgG, concentrated -15 times using a Speed-Vac (Savant Instruments, Fullerton, CA), was used in TSI and TBI assays with the wild-type TSH receptor, as described above.
Results
We studied the ability ofthree TSH-LH/CG receptor chimeras to function in TSI and TBI assays. Each of these chimeras contain different, overlapping regions of the TSH receptor (15) , and binds TSH with high affinity (Fig. 1) . Only the chimera with TSH receptor domains ABC (TSH-LHR-6) responded to a series of IgG from patients with autoimmune thyroid disease selected to cover a wide range of TSI activities (Fig. 2 ). The chimeras with TSH receptor domains CD (TSH-LHR-10) and DE (TSH-LHR-9) were unresponsive. The lack of response ofchimera TSH-LHR-9 was anticipated because it fails to transduce a signal with TSH stimulation (15) . Chimera TSH-LHR-l0, however, does transduce a signal upon TSH binding. A different spectrum of responses was observed when the TSH-LH/CG chimeras were used in a TBI, rather than in a TSI, assay (Fig. 3) . IgG from autoimmune thyroid disease patients' sera that competed for TSH binding to the wild-type TSH receptor were approximately equipotent in an assay using the TSH-LH/CG receptor chimera with the TSH receptor domains DE (TSH-LHR-9). Dramatically, these IgG did not inhibit TSH binding to the chimera with TSH receptor domains CD (TSH-LHR-l0). When assayed with chimera TSH-LHR-6 (TSH receptor domains ABC), TBI activity was very weak relative to that in the assay with the wild-type TSH receptor, in contrast to the excellent functional response ofthis chimera to stimulatory IgG.
The divergence in the thyroid-stimulatory and TSH binding-inhibitory responses observed in the foregoing studies raised the possibility ofthe preferential binding ofIgG with TSI activity to domains ABC, and IgG with TBI activity to domains were also subjected to the same immunoadsorption procedure. The elution buffer containing the IgG was concentrated 15-fold and then tested for both stimulatory (A) and TSH binding-inhibitory (B) activity using CHO cells expressing the wild-type TSH receptor (see Methods). TSI data are expressed as a percentage of values obtained with assay buffer alone. TBI data are expressed as follows: [l-(radioactivity of test IgG/radioactivity of assay buffer)] X 100(%). Each bar represents the mean±SE ofdata obtained in triplicate experiments. Significance of differences (t test) between IgG adsorbed to the indicated chimeras and the pSV2NEO control; *P < 0.05, **P < 0.01.
were equally effective in the affinity purification of both TSI and TBI activities when tested with the wild-type receptor (Fig.  4) . As controls, CHO cells stably transfected with pSV2NEO could not affinity purify IgG with either TSI or TBI activity. A similar lack of adsorption was seen with a chimeric receptor (TSH-LHR-1 1; Fig. 1 ) containing the entire extracellular domain of the LH/CG receptor (data not shown).
Finally, the interaction between the thyroid-stimulatory and TSH binding-inhibitory antibodies was examined (Table  I) . Two nonstimulatory IgG with potent TBI activity (IgG Nos. 12 and 13) inhibited the activity ofstimulatory IgG (IgG Nos. 1 and 2) when tested with the wild-type TSH receptor. In contrast, these two inhibitory IgG had no effect on TSI activity when tested in chimera TSH-LHR-6 that has only TSH receptor domains ABC. TSH-LHR-9 cannot be tested for potential inhibition of TSI activity because this receptor chimera cannot transduce a cAMP signal.
Discussion
Present evidence suggests that the sera of some patients with autoimmune thyroid disease contain a mixture of stimulatory or inhibitory TSH receptor antibodies (1, 7, 20) . Although the epitopes for these antibodies are unknown, the present concept is that they correspond to the TSH binding site on the TSH receptor. Contradictory data exist for and against this hypothesis. Evidence and TSH binding-inhibitory activities (22) (23) (24) , but none of these antibodies have been proven to be against the TSH receptor. The reported ability of IgG from patients with autoimmune thyroid disease to immunoprecipitate TSH -TSH receptor complexes (25) (26) (27) (28) would also support the existence of separate binding sites for TSH receptor antibodies and TSH. However, these findings have been disputed (1) .
Other data support the contrary thesis, namely that the antibody and ligand binding sites are the same. Thus, IgG from almost all patients with active Graves' disease have TSH binding-inhibitory activity (29) , although it is not proven that this activity is inherent to the same IgG molecules with thyroidstimulatory activity. Further, inhibitory antibodies are reported to become stimulatory after they are bound by antiIgG (30) .
This descriptive era is now drawing to a close with the recent advances in defining epitopes and ligand binding sites at the molecular level. Epitopes typically contain [14] [15] [16] [17] [18] [19] [20] [21] amino acids contributed to by 2-4 discontinuous regions in the primary amino acid sequence (17, 18) . There is recent evidence for the localization ofa number ofthese TSH receptor autoantibody binding regions. Thus, deletional and nonhomologous substitutions ofamino acids 38-45 in the TSH receptor suggest that this segment may be important in TSH and thyroid-stimulatory antibody functional activity (31). In these studies, however, the three-dimensional integrity ofthe TSH receptor could not be confirmed. Antibody binding to synthetic peptides suggests that TSH receptor amino acids 32-56 (overlapping with the above mentioned region), 309-317, and 123-131 may also contribute to the TSH receptor epitopes (32, 33) . While these amino acid sequences may be part ofthe TSH binding sites, the binding affinity ofantibodies for synthetic peptides is generally low, and the data cannot be regarded as definitive.
In this study, wild-type TSH receptor (8) and TSH-LH/CG receptor extracellular domain chimeras (15) were used to compare the binding domain for TSH with those for thyroid-stimulatory and TSH binding-inhibitory autoantibodies. The proven preservation of chimera functional integrity makes the data more definitive than those obtained using deletional/nonhomologous mutagenesis or synthetic peptides. A recognized limitation to the chimeric approach, however, is that the binding or function of an antibody may not be altered if the homologous regions substituted have functions common to both receptors. Both the TSH and LH/CG receptors interact with the common alpha-subunit of the glycoprotein hormones. Using TSH-LH/ CG receptor chimeras, it may, therefore, not be possible to identify the epitopes for antibodies that preferentially bind to alpha-subunit binding site(s). However, the inability ofthe chimera with the entire LH/CG receptor extracellular domain (TSH-LHR-11) to affinity purify TSH receptor autoantibodies suggests the lesser importance of TSH alpha-subunit binding site(s) in autoantibody binding to the TSH receptor.
Two conclusions can be drawn from our data (shown schematically in Fig. 5 ). First, TSH receptor antibodies bind to regions in both domains ABC and DE of the TSH receptor. This phenomenon is similar to that previously demonstrated for TSH binding to the receptor (15) and presumably occurs because segments in these domains are brought into apposition by folding of the globular receptor protein. The epitopes for stimulatory and inhibitory antibodies must be included in both domains ABC and DE of the TSH receptor because chimeras TSH-LHR-6 (TSH receptor domains ABC) and TSH-LHR-9 (TSH receptor domains DE) are both capable ofaffinity purifying these antibodies.
A second conclusion from our data is that the epitopes for TSH receptor antibodies are unlikely to be identical to the TSH binding site. Evidence for this conclusion is that chimera TSH-LHR-10, which displays functional, high affinity TSH binding, does not respond functionally to TSI; further, TBI does not compete for TSH binding to this mutant receptor. The nonidentity in the hormone and antibody binding sites is likely to be inherent primarily in domains ABC, rather than in domains DE, of the receptor. This is because TSH receptor antibodies compete less well for TSH binding to chimera TSH-LHR-6 (TSH receptor domains ABC) than to the wild-type TSH receptor. In contrast, TSH receptor antibodies compete approximately equally for TSH binding to chimera TSH-LHR-9 (TSH receptor domains DE) and to the wild-type TSH receptor.
Not It must be acknowledged that the foregoing interpretations rest on the premise that antibody inhibition of TSH binding reflects at least partial overlap of their respective binding sites rather than steric, or allo-steric, effects of antibody on TSH binding. We also cannot exclude the possibility that stimulatory and inhibitory TSH receptor antibodies bind to the same epitope in domains ABC, but with different affinities. In this case, TSH binds to chimera TSH-LHR-6 with higher affinity than do the TSH receptor autoantibodies.
In conclusion, these data provide the first indication at the molecular level that the epitopes for TSH receptor antibodies may not be identical to the TSH binding sites on the TSH receptor. Further mutagenesis studies may be helpful for fine epitope mapping of TSH receptor autoantibodies.
